EMA Authorised: Mayzent (siponimod fumaric acid) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised Mayzent (siponimod) for relapsing-remitting multiple sclerosis in the EU, with Novartis Europharm Limited as the marketing authorization hold…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• MAYZENT (siponimod)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting. MAH: Novartis Europharm Limited. Decision date: 11/09/2025